{"id":16311,"date":"2023-07-11T22:43:00","date_gmt":"2023-07-11T14:43:00","guid":{"rendered":"https:\/\/flcube.com\/?p=16311"},"modified":"2024-12-02T22:51:15","modified_gmt":"2024-12-02T14:51:15","slug":"zhejiang-doer-biologics-partners-with-biontech-for-global-development-of-innovative-biological-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16311","title":{"rendered":"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs"},"content":{"rendered":"\n

Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing agreement with Germany’s BioNTech SE (NASDAQ: BNTX<\/a>). Under the terms of this deal, Doer Bio will provide BioNTech with a global license to research, develop, manufacture, and commercialize innovative biological drugs targeting an undisclosed therapeutic target, leveraging an innovative discovery made by Doer Bio. In return, Doer Bio will receive advance payments and is eligible for potential development, regulatory, and commercial milestone payments.<\/p>\n\n\n\n

Doer Bio’s Proprietary Technologies and Focus on Metabolic Diseases and Cancers<\/strong>
Doer Bio specializes in the discovery and development of multi-specific biological drugs aimed at treating metabolic diseases and cancers. The company boasts several proprietary platform technologies, including xLONGylation, MultiBody, AccuBody, and SMART-VHBody, which position it at the forefront of innovative drug development. These technologies enable the creation of cutting-edge therapies that have the potential to transform the treatment landscape for various diseases.<\/p>\n\n\n\n

Collaboration with BioNTech to Accelerate Drug Discovery and Commercialization<\/strong>
The partnership with BioNTech SE is a strategic move that will accelerate the global development and commercialization of the targeted biological drugs. By combining Doer Bio’s innovative discovery with BioNTech’s extensive experience in the field, the collaboration aims to bring new and effective treatments to patients worldwide.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[342,2508,1124],"class_list":["post-16311","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biontech","tag-doer-biologics","tag-nasdaq-bntx"],"yoast_head":"\nZhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing agreement with Germany's BioNTech SE (NASDAQ: BNTX). Under the terms of this deal, Doer Bio will provide BioNTech with a global license to research, develop, manufacture, and commercialize innovative biological drugs targeting an undisclosed therapeutic target, leveraging an innovative discovery made by Doer Bio. In return, Doer Bio will receive advance payments and is eligible for potential development, regulatory, and commercial milestone payments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16311\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16311\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-11T14:43:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-02T14:51:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16311#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16311\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs\",\"datePublished\":\"2023-07-11T14:43:00+00:00\",\"dateModified\":\"2024-12-02T14:51:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16311\"},\"wordCount\":228,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BioNTech\",\"Doer Biologics\",\"NASDAQ: BNTX\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16311#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16311\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16311\",\"name\":\"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-11T14:43:00+00:00\",\"dateModified\":\"2024-12-02T14:51:15+00:00\",\"description\":\"Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing agreement with Germany's BioNTech SE (NASDAQ: BNTX). Under the terms of this deal, Doer Bio will provide BioNTech with a global license to research, develop, manufacture, and commercialize innovative biological drugs targeting an undisclosed therapeutic target, leveraging an innovative discovery made by Doer Bio. In return, Doer Bio will receive advance payments and is eligible for potential development, regulatory, and commercial milestone payments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16311#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16311\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16311#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs - Insight, China's Pharmaceutical Industry","description":"Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing agreement with Germany's BioNTech SE (NASDAQ: BNTX). Under the terms of this deal, Doer Bio will provide BioNTech with a global license to research, develop, manufacture, and commercialize innovative biological drugs targeting an undisclosed therapeutic target, leveraging an innovative discovery made by Doer Bio. In return, Doer Bio will receive advance payments and is eligible for potential development, regulatory, and commercial milestone payments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16311","og_locale":"en_US","og_type":"article","og_title":"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=16311","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-11T14:43:00+00:00","article_modified_time":"2024-12-02T14:51:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16311#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16311"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs","datePublished":"2023-07-11T14:43:00+00:00","dateModified":"2024-12-02T14:51:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16311"},"wordCount":228,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BioNTech","Doer Biologics","NASDAQ: BNTX"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16311#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16311","url":"https:\/\/flcube.com\/?p=16311","name":"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-11T14:43:00+00:00","dateModified":"2024-12-02T14:51:15+00:00","description":"Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing agreement with Germany's BioNTech SE (NASDAQ: BNTX). Under the terms of this deal, Doer Bio will provide BioNTech with a global license to research, develop, manufacture, and commercialize innovative biological drugs targeting an undisclosed therapeutic target, leveraging an innovative discovery made by Doer Bio. In return, Doer Bio will receive advance payments and is eligible for potential development, regulatory, and commercial milestone payments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16311#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16311"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16311#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16311"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16311\/revisions"}],"predecessor-version":[{"id":16312,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16311\/revisions\/16312"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}